ImmuPharma (IMM) Competitors GBX 2.41 -0.14 (-5.49%) As of 04/17/2025 11:43 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock IMM vs. TRX, COS, FUM, C4XD, DDDD, OKYO, SAR, AOR, OPTI, and ARECShould you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include Tissue Regenix Group (TRX), Collagen Solutions plc (COS.L) (COS), Futura Medical (FUM), C4X Discovery (C4XD), 4D pharma (DDDD), OKYO Pharma (OKYO), Sareum (SAR), AorTech International (AOR), OptiBiotix Health (OPTI), and Arecor Therapeutics (AREC). These companies are all part of the "biotechnology" industry. ImmuPharma vs. Tissue Regenix Group Collagen Solutions plc (COS.L) Futura Medical C4X Discovery 4D pharma OKYO Pharma Sareum AorTech International OptiBiotix Health Arecor Therapeutics Tissue Regenix Group (LON:TRX) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk. Which has more risk and volatility, TRX or IMM? Tissue Regenix Group has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Which has better earnings and valuation, TRX or IMM? Tissue Regenix Group has higher revenue and earnings than ImmuPharma. Tissue Regenix Group is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTissue Regenix Group£31.98M1.03-£1.11M-£0.97-37.58ImmuPharma-£71.31K-143.66-£2.51M-£0.58-4.17 Do insiders and institutionals have more ownership in TRX or IMM? 37.0% of Tissue Regenix Group shares are owned by institutional investors. Comparatively, 17.4% of ImmuPharma shares are owned by institutional investors. 47.3% of Tissue Regenix Group shares are owned by insiders. Comparatively, 48.3% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is TRX or IMM more profitable? ImmuPharma has a net margin of 3,519.56% compared to Tissue Regenix Group's net margin of -3.46%. Tissue Regenix Group's return on equity of -2.87% beat ImmuPharma's return on equity.Company Net Margins Return on Equity Return on Assets Tissue Regenix Group-3.46% -2.87% 0.50% ImmuPharma 3,519.56%-131.41%-43.00% Does the media favor TRX or IMM? In the previous week, Tissue Regenix Group's average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score. Company Overall Sentiment Tissue Regenix Group Neutral ImmuPharma Neutral Does the MarketBeat Community believe in TRX or IMM? ImmuPharma received 104 more outperform votes than Tissue Regenix Group when rated by MarketBeat users. Likewise, 76.44% of users gave ImmuPharma an outperform vote while only 69.53% of users gave Tissue Regenix Group an outperform vote. CompanyUnderperformOutperformTissue Regenix GroupOutperform Votes16269.53% Underperform Votes7130.47% ImmuPharmaOutperform Votes26676.44% Underperform Votes8223.56% SummaryTissue Regenix Group beats ImmuPharma on 7 of the 13 factors compared between the two stocks. Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMM vs. The Competition Export to ExcelMetricImmuPharmaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£10.25M£121.00M£5.30B£2.48BDividend Yield0.77%3.75%5.45%4.92%P/E Ratio-4.173.0521.86129.92Price / Sales-143.664,230.36380.66232,415.27Price / Cash20.5013.1938.2628.16Price / Book3.7334.276.454.40Net Income-£2.51M-£91.73M£3.22B£5.83B1 Month Performance-30.35%-5.17%-9.74%-1.34%1 Year Performance2.55%83.94%11.49%40.97% ImmuPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMImmuPharmaN/AGBX 2.41-5.5%N/A+7.6%£10.25M£-71,310.29-4.1713Gap DownTRXTissue Regenix GroupN/AGBX 37.25-2.0%N/A-40.8%£33.58M£31.98M-38.46120High Trading VolumeCOSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350FUMFutura MedicalN/AGBX 9.88+2.1%N/A-74.9%£30.80M£8.68M-8.1512Earnings ReportC4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718,000.00-1.08106OKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownSARSareumN/AGBX 17.40-0.6%N/A-36.4%£21.74MN/A-4.123,211AORAorTech InternationalN/AN/AN/AN/A£19.99M£539,000.00-33.383OPTIOptiBiotix HealthN/AGBX 15.90-2.2%N/A+2.8%£15.57M£590,009.23-5.031Gap UpARECArecor TherapeuticsN/AGBX 36-5.3%N/A-69.3%£13.59M£6.04M-1.2710Gap Up Related Companies and Tools Related Companies TRX Alternatives COS Alternatives FUM Alternatives C4XD Alternatives DDDD Alternatives OKYO Alternatives SAR Alternatives AOR Alternatives OPTI Alternatives AREC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:IMM) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
